GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Neovasc Inc (TSX:NVCN) » Definitions » ROIC %

Neovasc (TSX:NVCN) ROIC % : -519.63% (As of Dec. 2022)


View and export this data going back to 2001. Start your Free Trial

What is Neovasc ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Neovasc's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2022 was -519.63%.

As of today (2024-04-26), Neovasc's WACC % is 12.34%. Neovasc's ROIC % is -309.62% (calculated using TTM income statement data). Neovasc earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Neovasc ROIC % Historical Data

The historical data trend for Neovasc's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neovasc ROIC % Chart

Neovasc Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -207.28 -395.31 -483.85 -390.11 -339.86

Neovasc Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -172.34 -215.61 -278.43 -249.51 -519.63

Competitive Comparison of Neovasc's ROIC %

For the Medical Devices subindustry, Neovasc's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neovasc's ROIC % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Neovasc's ROIC % distribution charts can be found below:

* The bar in red indicates where Neovasc's ROIC % falls into.



Neovasc ROIC % Calculation

Neovasc's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2022 is calculated as:

ROIC % (A: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2021 ) + Invested Capital (A: Dec. 2022 ))/ count )
=-45.837 * ( 1 - -0.06% )/( (14.541 + 12.449)/ 2 )
=-45.8645022/13.495
=-339.86 %

where

Neovasc's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2022 is calculated as:

ROIC % (Q: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2022 ) + Invested Capital (Q: Dec. 2022 ))/ count )
=-68.056 * ( 1 - -0.18% )/( (13.792 + 12.449)/ 2 )
=-68.1785008/13.1205
=-519.63 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2022) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neovasc  (TSX:NVCN) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Neovasc's WACC % is 12.34%. Neovasc's ROIC % is -309.62% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Neovasc ROIC % Related Terms

Thank you for viewing the detailed overview of Neovasc's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Neovasc (TSX:NVCN) Business Description

Traded in Other Exchanges
N/A
Address
13562 Maycrest Way, Suite 5138, Richmond, BC, CAN, V6V 2J7
Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.

Neovasc (TSX:NVCN) Headlines

From GuruFocus

Neovasc Announces Progress on COSIRA-II Clinical Trial

By Value_Insider Value_Insider 11-28-2022

Neovasc to Participate in H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 07-02-2022

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

By GuruFocusNews GuruFocusNews 06-15-2022

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

By PurpleRose PurpleRose 07-15-2022

Neovasc to Report Third Quarter Financial Results on November 10, 2022

By Value_Insider Value_Insider 10-27-2022

Shockwave Medical to Acquire Neovasc

By Stock market mentor Stock market mentor 01-17-2023

Neovasc to Participate in H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 06-22-2022